Anakinra treatment in drug-resistant Behcet’s disease: a case series

Clinical Rheumatology

Volumn 34, Issue 7, 2015, Pages 1293-1301

  Cantarini, Luca ^a   Vitale, Antonio ^a   Scalini, Perla ^b   Dinarello, Charles A ^c,d   Rigante, Donato ^e   Franceschini, Rossella ^a   Simonini, Gabriele ^b   Borsari, Giulia ^a   Caso, Francesco ^f   Lucherini, Orso Maria ^a   Frediani, Bruno ^a   Bertoldi, Ilaria ^a   Punzi, Leonardo ^f   Galeazzi, Mauro ^a   Cimaz, Rolando ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Behcet's disease; Biologic agents; Interleukin 1 inhibition; Uveitis

Indexed keywords

ANTITHROMBIN III; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; CYCLOSPORIN; DEFLAZACORT; ETANERCEPT; HLA B51 ANTIGEN; INFLIXIMAB; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROTEIN C; PROTEIN S; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; BEHCET DISEASE; CAUCASIAN; CHILD; CHRONIC DIARRHEA; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ERYTHEMA NODOSUM; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; IRIDOCYCLITIS; LOW DRUG DOSE; MALE; MIDDLE AGED; ONSET AGE; PRIORITY JOURNAL; RETINA VASCULITIS; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SCHOOL CHILD; SKIN DEFECT; SKIN ULCER; UVEITIS; VASCULITIC RASH; VEIN THROMBOSIS; YOUNG ADULT; ALLELE; BEHCET SYNDROME; BLOOD; CASE REPORT; DRUG RESISTANCE; GENETICS; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; BIOMARKERS; CHILD; DRUG RESISTANCE; FEMALE; HLA-B51 ANTIGEN; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 84931571929     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2443-8     Document Type: Review

References (46)

1. International Study Group for Behcet disease (1990) Criteria for diagnosis of Behcet's disease. Lancet 335:1078–1080
2. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76
3. Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G (2011) Evaluation of current therapeutic strategies in Behçet's disease. Clin Rheumatol 30:157–163
4. Pipitone N, Olivieri I, Padula A, D'angelo S, Nigro A, Zuccoli G, Boiardi L, Salvarani C (2008) Infliximab for the treatment of neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum 59:285–290
5. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behçet disease responsive to anakinra. Ann Intern Med 149:284–286
6. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 71:563–566
7. Touitou I, Magne X, Molinari N, Navarro A, Quellec AL, Picco P, Seri M, Ozen S, Bakkaloglu A, Karaduman A, Garnier JM, Demaille J, Koné-Paut I (2000) MEFV mutations in Behçet's disease. Hum Mutat 16:271–272
8. Amoura Z, Dodé C, Hue S, Caillat-Zucman S, Bahram S, Delpech M, Grateau G, Wechsler B, Piette JC (2005) Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease. Arthritis Rheum 52:608–611
9. Rigante D (2012) The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 11:348–356
10. Kotter I, Hamuryudan V, Ozturk ZE, Yazici H (2010) Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 22:278–283
11. Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Behçet's disease. Clin Exp Rheumatol 30:S115
12. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease. Ann Rheum Dis 71:1589–1591
13. Direskeneli H (2006) Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 45:1461–1465
14. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S, Yazici H, Expert Committee EULAR (2008) EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67:1656–1662
15. Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm 11:8793
16. Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villiger PM (1997) Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 24:12832
17. Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61–70
18. Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M (2009) Safety and efficacy of etanercept in children with juvenile-onset Behcet's disease. Int J Immunopathol Pharmacol 22:551–555
19. Atzeni F, Leccese P, D’Angelo S, Sarzi-Puttini P, Olivieri I (2010) Successful treatment of leg ulcers in Behcet's disease using adalimumab plus methotrexate after the failure of infliximab. Clin Exp Rheumatol 28:S94
20. Belzunegui J, Lopez L, Paniagua I, Intxausti JJ, Maiz O (2008) Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behcet's disease. Clin Exp Rheumatol 26:S1334
21. Leccese P, D’Angelo S, Angela P, Coniglio G, Olivieri I (2010) Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab. Clin Exp Rheumatol 28:S102
22. Lee SW, Lee SY, Kim KN, Jung JK, Chung WT (2010) Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease: a case report. Clin Rheumatol 29:91–93
23. Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye 21:824–825
24. Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 31:243–245
25. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM (2007) Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 66:565–566
26. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70:2155–2158
27. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P (2010) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62:258–267
28. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70:747–754
29. Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S, Plebani A, Merlini G (2011) Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70:1511–1512
30. Zhou ZY, Chen SL, Shen N, Lu Y (2012) Cytokines and Behcet's disease. Autoimmun Rev 11:699–704
31. Akman-Demir G, Tüzün E, Içöz S, Yeşilot N, Yentür SP, Kürtüncü M, Mutlu M, Saruhan-Direskeneli G (2008) Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine 44:373–376
32. Akdeniz N, Esrefoglu M, Keleş MS, Karakuzu A, Atasoy M (2004) Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore 33:596–599
33. Borhani Haghighi A, Ittehadi H, Nikseresht AR, Rahmati J, Poorjahromi SG, Pourabbas B, Nazarinia MA, Habibagahi Z, Fattahi MJ, Ghaderi A (2009) CSF levels of cytokines in neuro-Behçet's disease. Clin Neurol Neurosurg 111:507–510
34. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652
35. Düzgün N, Ayaşlioğlu E, Tutkak H, Aydintuğ OT (2005) Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease. Rheumatol Int 25:1–5
36. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanç M, Capo C (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549
37. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA, Maseri A (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99:2079–2084
38. Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A (1995) Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity. Isr J Med Sci 31:345–348
39. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT (2002) Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 32:97–105
40. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E, Apte RN (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 175:8200–8208
41. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet's Disease Research Group Of Japan (2012) Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 130:592–598
42. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P (2007) Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 51:191–196
43. Perra D, Alba MA, Callejas JL, Mesquida M, Ríos-Fernández R, Adán A, Ortego N, Cervera R, Espinosa G (2012) Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 51:1825–1831
44. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y (2011) Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 21:184–1891
45. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ (2003) Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110:1449–1453
46. Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S (2011) Infliximab for patients with neuro-Behcet's disease: case series and literature review. Clin Rheumatol 30:1007–1012